EANM’09 – CME Session XIII
October 14, 2009, 10:00 – 11:30
Moderator: M. De Jong (Rotterdam)
Co-Moderator: A. Schubiger (Villigen/Psi)
|Y. Haemisch (Paris, BIOSCAN):
Imaging Biomarkers in Preclinical Drug Development
|F. Lordick (Heidelberg):
Imaging Biomarkers during Systemic Therapy of Cancer Patients
|S. Ametamey (Zurich):
Monitoring of Gene Therapy
- Gain insights in the preclinical and clinical process of drug development.
- Understand the role of pharmacodynamics in clinical decision making referring physicians.
- Develop a strategy how to offer biomarker imaging to cancer patients and clinicians
- Adopt knowledge and techniques to provide state-of-the-art, high-end nuclear imaging service at research units and hospitals.
This continuing education session addresses research fellows and nuclear physicians active or interested in performance and interpretation of preclinical and clinical nuclear cancer studies. It will cover a review of current imaging methodology for drug development as well as insights into the clinical as well as experimental use of biomarker imaging. By getting an overview of the current state-of-the art and recent developments, this sessions seeks to provide a foundation to participants for refining their research and clinical practice.
Biomarkers, Cancer, Therapy Monitoring, Drug Development